Charles Schwab Investment Management Inc Nymox Pharmaceutical Corp Transaction History

Charles Schwab Investment Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$1.46 - $2.48 $138,694 - $235,590	-94,996 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$2.22 - $3.39 $22,330 - $34,100	10,059 Added 11.84%	94,996 $211,000
Q2 2020 Aug 14, 2020	BUY	$2.1 - $4.6 $178,367 - $390,710	84,937 New	84,937 $302,000
Q2 2019 Aug 09, 2019	SELL	$1.33 - $2.12 $80,332 - $128,048	-60,400 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$2.46 - $3.7 $24,600 - $37,000	10,000 Added 19.84%	60,400 $149,000
Q3 2017 Nov 13, 2017	BUY	$3.36 - $4.02 $169,344 - $202,607	50,400	50,400 $193,000

150K

Ticker NYMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,265,000
Market Cap $42.9M
Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperpl...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.